BR112018014150A2 - anticorpos monoclonais humanizados imunoestimulantes contra interleucina-2 humana, e proteínas de fusão dos mesmos - Google Patents
anticorpos monoclonais humanizados imunoestimulantes contra interleucina-2 humana, e proteínas de fusão dos mesmosInfo
- Publication number
- BR112018014150A2 BR112018014150A2 BR112018014150A BR112018014150A BR112018014150A2 BR 112018014150 A2 BR112018014150 A2 BR 112018014150A2 BR 112018014150 A BR112018014150 A BR 112018014150A BR 112018014150 A BR112018014150 A BR 112018014150A BR 112018014150 A2 BR112018014150 A2 BR 112018014150A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunostimulating
- human interleukin
- monoclonal antibodies
- fusion proteins
- humanized monoclonal
- Prior art date
Links
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 title abstract 2
- 102000055277 human IL2 Human genes 0.000 title abstract 2
- 102000037865 fusion proteins Human genes 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 230000003308 immunostimulating effect Effects 0.000 title 1
- 101100506090 Caenorhabditis elegans hil-2 gene Proteins 0.000 abstract 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/246—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente invenção se refere a anticorpos que se ligam à interleucina-2 humana (hil-2). a invenção se refere, mais especificamente, a anticorpos humanizados que se ligam especificamente a um epítopo particular de hil-2 e, quando ligados a esse epítopo, exibem uma capacidade exclusiva de inibir a ligação de hil-2 a cd25.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662277113P | 2016-01-11 | 2016-01-11 | |
PCT/IB2017/050127 WO2017122130A1 (en) | 2016-01-11 | 2017-01-11 | Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018014150A2 true BR112018014150A2 (pt) | 2018-12-11 |
Family
ID=57882113
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018014150A BR112018014150A2 (pt) | 2016-01-11 | 2017-01-11 | anticorpos monoclonais humanizados imunoestimulantes contra interleucina-2 humana, e proteínas de fusão dos mesmos |
Country Status (14)
Country | Link |
---|---|
US (2) | US10889643B2 (pt) |
EP (1) | EP3402819A1 (pt) |
JP (1) | JP6993699B2 (pt) |
KR (1) | KR20180100224A (pt) |
CN (2) | CN116003593A (pt) |
AU (1) | AU2017208133B2 (pt) |
BR (1) | BR112018014150A2 (pt) |
CA (1) | CA3009001A1 (pt) |
EA (1) | EA039865B1 (pt) |
HK (1) | HK1257518A1 (pt) |
IL (1) | IL260218B2 (pt) |
MA (1) | MA43859A (pt) |
MX (1) | MX2018008592A (pt) |
WO (1) | WO2017122130A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CR20160425A (es) * | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
AU2017214277B2 (en) * | 2016-02-01 | 2020-02-27 | Eli Lilly And Company | Parathyroid hormone – anti-RANKL antibody fusion compounds |
JP2019534710A (ja) * | 2016-09-28 | 2019-12-05 | ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー | インターロイキン2に結合する抗体およびその使用 |
AU2018234810B2 (en) | 2017-03-15 | 2023-05-11 | Pandion Operations, Inc. | Targeted immunotolerance |
SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US20190225689A1 (en) * | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
WO2019168791A2 (en) * | 2018-02-28 | 2019-09-06 | The Board Of Trustees Of The Leland Stanford Junior University | Single-chain il-2/antibody fusions that selectively activate regulatory t cells |
WO2019239213A2 (en) * | 2018-06-01 | 2019-12-19 | Medicenna Therapeutics Inc. | Uses and methods for oncolytic virus targeting of il-4/il-13 and fusions thereof |
TW202110885A (zh) | 2019-05-20 | 2021-03-16 | 美商潘迪恩治療公司 | 靶向MAdCAM之免疫耐受性 |
EP4103607A4 (en) * | 2020-02-16 | 2023-12-20 | Aulos Bioscience, Inc | ANTI-IL-2 ANTIBODIES PRODUCED BY ENGINEERING |
EP4107187A1 (en) | 2020-02-21 | 2022-12-28 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
CN111825763B (zh) * | 2020-07-15 | 2022-04-19 | 扬州大学 | 流感病毒ha蛋白茎部特异性单克隆抗体及其制备方法和应用 |
AU2022246048A1 (en) | 2021-03-26 | 2023-08-31 | Innate Pharma | Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging |
WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
KR20240019297A (ko) | 2021-06-09 | 2024-02-14 | 이나뜨 파르마 에스.에이. | Nkp46, 사이토카인 수용체, 종양 항원 및 cd16a 에 결합하는 다중특이적 단백질 |
WO2023061005A1 (zh) | 2021-10-14 | 2023-04-20 | 徕特康(苏州)生物制药有限公司 | 新型抗体-细胞因子融合蛋白及其制备方法和用途 |
US11773160B1 (en) | 2022-08-05 | 2023-10-03 | Anaveon AG | Immune-stimulating IL-2 fusion proteins |
CN117700535B (zh) * | 2024-02-05 | 2024-04-26 | 北京纳百生物科技有限公司 | 一种猫泛白细胞减少症病毒vp2蛋白单克隆抗体及其应用 |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE434680B (sv) | 1983-01-21 | 1984-08-06 | Karl Arne Lundblad | Anvendning av en saltlosning av monoklonala antikroppar med relativt hog salthalt vid blodgruppsbestemning |
CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
CA1340853C (en) | 1983-12-23 | 1999-12-21 | Hsiang-Fu Kung | Purification of recombinant interleukin-2 |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
DE69738749D1 (de) | 1996-08-16 | 2008-07-17 | Schering Corp | Zelloberflächen-antigen aus säugetieren und verwandte reagenzien |
US6111090A (en) | 1996-08-16 | 2000-08-29 | Schering Corporation | Mammalian cell surface antigens; related reagents |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ES2301198T3 (es) | 1997-06-12 | 2008-06-16 | Novartis International Pharmaceutical Ltd. | Polipeptidos artificiales de anticuerpos. |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
AU1102399A (en) | 1997-10-21 | 1999-05-10 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 |
US6689607B2 (en) | 1997-10-21 | 2004-02-10 | Human Genome Sciences, Inc. | Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2 |
CA2319236A1 (en) | 1998-02-09 | 1999-08-12 | Genentech, Inc. | Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same |
DK1196186T3 (da) | 1999-07-12 | 2008-03-03 | Genentech Inc | Stimulering eller inhibering af angiogenese og kardiovaskularisation med tumornekrosefaktorligand/receptorhomologer |
JP2003530838A (ja) | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
MXPA05006828A (es) | 2002-12-23 | 2005-09-08 | Wyeth Corp | Anticuerpos contra pd-1, y sus usos. |
EP2572714A1 (en) | 2002-12-30 | 2013-03-27 | 3M Innovative Properties Company | Immunostimulatory Combinations |
RU2369636C2 (ru) | 2003-05-23 | 2009-10-10 | Уайт | Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения |
US20050048054A1 (en) | 2003-07-11 | 2005-03-03 | Shino Hanabuchi | Lymphocytes; methods |
EP1692318A4 (en) | 2003-12-02 | 2008-04-02 | Genzyme Corp | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER |
GB0409799D0 (en) | 2004-04-30 | 2004-06-09 | Isis Innovation | Method of generating improved immune response |
EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
WO2006105021A2 (en) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Gitr binding molecules and uses therefor |
SI2161336T1 (sl) | 2005-05-09 | 2013-11-29 | Ono Pharmaceutical Co., Ltd. | Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki |
CA2609234C (en) | 2005-06-01 | 2014-04-22 | Micromet Ag | Anti-il2 antibodies |
AU2006259536A1 (en) | 2005-06-15 | 2006-12-28 | Schering Corporation | Anti-IGF1R antibody formulations |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
EP1981969A4 (en) | 2006-01-19 | 2009-06-03 | Genzyme Corp | ANTI-GITRANT ANTIBODIES FOR THE TREATMENT OF CANCER |
BRPI0707796A2 (pt) | 2006-02-15 | 2011-05-10 | Imclone Systems Inc | formulaÇço, e, mÉtodo de tratamento |
AU2007214426A1 (en) * | 2006-02-16 | 2007-08-23 | Nascent Biologics, Inc. | Methods for improving immune function and methods for prevention or treatment of disease in a mammalian subject |
EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
CN104548091A (zh) | 2008-02-11 | 2015-04-29 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
WO2010003118A1 (en) | 2008-07-02 | 2010-01-07 | Trubion Pharmaceuticals, Inc. | Tgf-b antagonist multi-target binding proteins |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
US20110223188A1 (en) | 2008-08-25 | 2011-09-15 | Solomon Langermann | Targeted costimulatory polypeptides and methods of use to treat cancer |
ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
JPWO2010030002A1 (ja) | 2008-09-12 | 2012-02-02 | 国立大学法人三重大学 | 外来性gitrリガンド発現細胞 |
PL3023438T3 (pl) | 2009-09-03 | 2020-07-27 | Merck Sharp & Dohme Corp. | Przeciwciała anty-gitr |
GB0919054D0 (en) | 2009-10-30 | 2009-12-16 | Isis Innovation | Treatment of obesity |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
DK2519543T3 (en) | 2009-12-29 | 2016-09-26 | Emergent Product Dev Seattle | HETERODIMER BINDING PROTEINS AND USE THEREOF |
PL2581113T3 (pl) | 2010-06-11 | 2018-11-30 | Kyowa Hakko Kirin Co., Ltd. | Przeciwciało anty-tim-3 |
EP3042917B1 (en) | 2010-08-12 | 2018-02-21 | Eli Lilly and Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
US20130108641A1 (en) | 2011-09-14 | 2013-05-02 | Sanofi | Anti-gitr antibodies |
PL2838548T3 (pl) | 2012-04-17 | 2024-02-05 | University Of Washington Through Its Center For Commercialization | Komórki z niedoborem hla klasy ii, komórki z niedoborem hla klasy i, zdolne do ekspresji białek hla klasy ii i ich zastosowania |
WO2013157105A1 (ja) | 2012-04-18 | 2013-10-24 | 公立大学法人大阪市立大学 | ムチンサブタイプ5ac特異的ヒト化抗体およびその利用 |
KR101549637B1 (ko) | 2012-06-08 | 2015-09-03 | 국립암센터 | 신규한 Th1 세포 전환용 에피토프 및 이의 용도 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
CN112587658A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
CN105188373B (zh) | 2013-05-18 | 2017-09-22 | 艾杜罗生物科技公司 | 抑制“干扰素基因刺激蛋白”依赖性信号传导的组合物和方法 |
MX354057B (es) | 2013-05-18 | 2018-02-09 | The Regents Of The Univ Of California Star | Composiciones y métodos para activar la señalización dependiente del "estimulador del gene de interferón". |
AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
WO2015109212A1 (en) | 2014-01-17 | 2015-07-23 | Pfizer Inc. | Anti-il-2 antibodies and compositions and uses thereof |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CR20160425A (es) | 2014-03-14 | 2017-05-26 | Novartis Ag | Moléculas de anticuerpos que se unen a lag-3 y usos de las mismas |
CN106604932A (zh) * | 2014-07-10 | 2017-04-26 | 诺华公司 | 人白细胞介素‑2的免疫刺激单克隆抗体 |
-
2017
- 2017-01-11 WO PCT/IB2017/050127 patent/WO2017122130A1/en active Application Filing
- 2017-01-11 CA CA3009001A patent/CA3009001A1/en active Pending
- 2017-01-11 US US16/069,146 patent/US10889643B2/en active Active
- 2017-01-11 MX MX2018008592A patent/MX2018008592A/es unknown
- 2017-01-11 CN CN202211356161.5A patent/CN116003593A/zh active Pending
- 2017-01-11 CN CN201780006001.9A patent/CN108473569B/zh active Active
- 2017-01-11 BR BR112018014150A patent/BR112018014150A2/pt unknown
- 2017-01-11 AU AU2017208133A patent/AU2017208133B2/en active Active
- 2017-01-11 KR KR1020187023058A patent/KR20180100224A/ko not_active Application Discontinuation
- 2017-01-11 JP JP2018536134A patent/JP6993699B2/ja active Active
- 2017-01-11 IL IL260218A patent/IL260218B2/en unknown
- 2017-01-11 EA EA201891582A patent/EA039865B1/ru unknown
- 2017-01-11 EP EP17701362.0A patent/EP3402819A1/en active Pending
- 2017-01-11 MA MA043859A patent/MA43859A/fr unknown
-
2018
- 2018-12-21 HK HK18116440.2A patent/HK1257518A1/zh unknown
-
2020
- 2020-12-17 US US17/124,930 patent/US11851484B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
IL260218A (en) | 2018-07-31 |
KR20180100224A (ko) | 2018-09-07 |
IL260218B2 (en) | 2023-04-01 |
US11851484B2 (en) | 2023-12-26 |
JP6993699B2 (ja) | 2022-02-03 |
EP3402819A1 (en) | 2018-11-21 |
IL260218B (en) | 2022-12-01 |
CN108473569A (zh) | 2018-08-31 |
US10889643B2 (en) | 2021-01-12 |
HK1257518A1 (zh) | 2019-10-25 |
US20210246200A1 (en) | 2021-08-12 |
EA201891582A1 (ru) | 2018-12-28 |
CA3009001A1 (en) | 2017-07-20 |
MX2018008592A (es) | 2018-12-10 |
WO2017122130A1 (en) | 2017-07-20 |
CN116003593A (zh) | 2023-04-25 |
CN108473569B (zh) | 2022-11-22 |
AU2017208133A1 (en) | 2018-07-05 |
US20190016797A1 (en) | 2019-01-17 |
JP2019511200A (ja) | 2019-04-25 |
MA43859A (fr) | 2018-11-21 |
AU2017208133B2 (en) | 2023-12-21 |
WO2017122130A9 (en) | 2018-02-01 |
EA039865B1 (ru) | 2022-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018014150A2 (pt) | anticorpos monoclonais humanizados imunoestimulantes contra interleucina-2 humana, e proteínas de fusão dos mesmos | |
BR112018067458A2 (pt) | anticorpos para tigit | |
CL2017002752A1 (es) | Anticuerpos heterodiméricos que unen anticuerpos cd3 y tumorales | |
CO2017013356A2 (es) | Anticuerpos de factor xi | |
EA201792413A1 (ru) | Антитела против cd71, активируемые антитела против cd71 и способы их применения | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201791164A1 (ru) | Гетеродимерные антитела, связывающие cd3 и cd38 | |
CU24533B1 (es) | Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos | |
MX2022011659A (es) | Proteinas de union a antigeno que se unen a pd-l1. | |
EA201791139A1 (ru) | Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены | |
AU2016219350A8 (en) | Humanized anti-MUC1* antibodies | |
PH12016501366A1 (en) | Novel anti-baff antibodies | |
BR112018070948A2 (pt) | anticorpos anti-psma e utilização dos mesmos | |
PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
BR112017015880A2 (pt) | anticorpos, usos e métodos | |
ZA201800804B (en) | Novel anti-human gpvi antibodies and uses thereof | |
MY194084A (en) | Interferon beta antibodies and uses thereof | |
EP3904387A4 (en) | MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO HUMAN TRBV-9 | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
PH12020500473A1 (en) | Antibody variants | |
AU2018279184A1 (en) | Anti-TrkB antibodies | |
MX2020002942A (es) | Variantes de anticuerpos. | |
EP3873514A4 (en) | MONOCLONAL ANTIBODIES AGAINST ELTD1 AND THEIR USES | |
EA202090580A3 (ru) | Триспецифичные связывающие молекулы и способы их применения | |
MA44925A1 (fr) | Anticorps hétérodimériques se liant aux antigènes cd3 et cd38 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |